UFIPRAZOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19N3O2S
Molecular Weight	329.417
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C2NC(SCC3=NC=C(C)C(OC)=C3C)=NC2=C1

InChI

InChIKey=XURCIPRUUASYLR-UHFFFAOYSA-N

InChI=1S/C17H19N3O2S/c1-10-8-18-15(11(2)16(10)22-4)9-23-17-19-13-6-5-12(21-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)

HIDE SMILES / InChI

Molecular Formula	C17H19N3O2S
Molecular Weight	329.417
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&ved=0ahUKEwi2wb7MyMLXAhURIuwKHS4iCLMQFghJMAY&url=https%3A%2F%2Fkuscholarworks.ku.edu%2Fbitstream%2Fhandle%2F1808%2F19459%2FOgilvie_ku_0099D_13918_DATA_1.pdf%3Bsequence%3D1&usg=AOvVaw3VOYBeS-_felBOQniqTuz_ | https://www.ncbi.nlm.nih.gov/pubmed/18818070

Ufiprazole (Omeprazole sulfide) is a metabolite of Omeprazole, which is a proton pump inhibitor. Omeprazole sulfide has been shown to be a direct-acting inhibitor of CYP2C19 in pooled human liver microsomes. Ufiprazole is also a weak BRS-3 agonist.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bombesin receptor subtype-3 2 Target ID: CHEMBL4080 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18818070	Partial Agonist 290		3.9 µM [EC50]
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&ved=0ahUKEwi2wb7MyMLXAhURIuwKHS4iCLMQFghJMAY&url=https%3A%2F%2Fkuscholarworks.ku.edu%2Fbitstream%2Fhandle%2F1808%2F19459%2FOgilvie_ku_0099D_13918_DATA_1.pdf%3Bsequence%3D1&usg=AOvVaw3VOYBeS-_felBOQniqTuz_	Inhibitor 8297		9.7 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide.	2006 May	16109480
Solubility of Omeprazole Sulfide in Different Solvents at the Range of 280.35-319.65 K.	2013	24319302

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Omeprazole sulfide was evaluated as direct-acting and MDI of CYP2C19 activity (S-mephenytoin 4´-hydroxylation) in pooled human liver microsomes (0.1 mg/mL) at a substrate concentration approximately equal to the Km (40 uM). Omeprazole sulfide has been shown to be a direct-acting inhibitor of CYP2C19 in pooled human liver microsomes with IC50 value of 9.7 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:49 GMT 2023` Edited by `admin` on `Fri Dec 15 15:30:49 GMT 2023`
Record UNII	6FFV1V867C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

UFIPRAZOLE

Official Name

English

OMEPRAZOLE MAGNESIUM IMPURITY C [EP IMPURITY]

Common Name

English

UFIPRAZOLE [INCI]

Common Name

English

ufiprazole [INN]

Common Name

English

OMEPRAZOLE SULFIDE

Common Name

English

OMEPRAZOLE IMPURITY C [EP IMPURITY]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29723